Measuring Oncological Value of Exercise and Statin

Launched by TAMPERE UNIVERSITY HOSPITAL · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how exercise and a medication called atorvastatin might help improve cancer treatment for patients with advanced cancers like breast, kidney, ovarian, and prostate cancer. The study aims to find out if participating in supervised exercise sessions during treatment can make the cancer drugs work better compared to exercising on your own. Additionally, researchers want to see if taking atorvastatin along with these guided exercise sessions will boost the effectiveness of the treatment.

To be eligible for this trial, participants need to be adults (18 years and older) with confirmed metastatic cancer (meaning the cancer has spread to other parts of the body) and must be starting their first round of specific cancer drug treatments. Patients with certain health conditions, such as severe liver or kidney problems, or those who cannot participate in physical activity, are not eligible. If you decide to join, you can expect to engage in group exercise sessions while receiving your cancer treatment, and you will have regular check-ins to monitor your progress and overall health throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started
• • Prostate cancer: First course of docetaxel treatment for metastatic prostate cancer.
• • Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.
• • Kidney cancer: medium-risk/high-risk kidney cancer according to the IMDC classification, for which 1st-line cancer drug treatment is started as tki monotherapy or as a combination treatment that includes tki medication. - the randomization of subjects is stratified according to gender
• • Ovarian cancer: stage III or IV cancer for which 1st-line chemotherapy treatment is started.
• • The patient agrees to the study and signs a written informed consent.
• • Adult (18 years=\>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study.
• • In women, the use of a reliable contraceptive during the intervention
• Exclusion Criteria:
• • High risk of bone fractures
• • Inability to physical exertion and/or unsuitability for cancer drug treatment
• • Poor co-operation ability for psychological reasons
• • Active use of cholesterol-lowering drugs
• • Severe liver or kidney failure
• • Troublesome side effects that occurred in the past during cholesterol medication
• • Continuous use of medicinal substances that interact with atorvastatin during the study period
• • A special group of subjects according to the Medical Research Act (1999/488) (e.g. minors and pregnant or lactating women)
• Exclusion criteria in patients who are already using statin medication before the study:
• • High risk of bone fractures
• • Inability to physical exertion and/or unsuitability for cancer drug treatment
• • Poor co-operation ability for psychological reasons
• • Severe liver or kidney failure
• • A special group of subjects according to the Medical Research Act (1999/488) (e.g. minors and pregnant or lactating women)